PEN250117P320000
- 107.30
- 0.000.00%
Penumbra Newsroom
Analysts Offer Insights on Healthcare Companies: Draegerwerk AG & Co. KGaA (GB:0K5E), DocMorris (Six Swiss: CH:DOCM) and Penumbra (PEN)
Penumbra Analyst Ratings
Wells Fargo Maintains Penumbra(PEN.US) With Buy Rating, Maintains Target Price $275
Citi Maintains Penumbra(PEN.US) With Hold Rating
Wells Fargo Sticks to Its Buy Rating for Penumbra (PEN)
BTIG Maintains Penumbra(PEN.US) With Buy Rating, Maintains Target Price $270
Penumbra (PEN) Receives a Buy From BTIG
RBC Capital Maintains Penumbra(PEN.US) With Buy Rating, Maintains Target Price $285
RBC Capital Sticks to Its Buy Rating for Penumbra (PEN)
RBC Capital Maintains Penumbra(PEN.US) With Buy Rating, Raises Target Price to $285
Penumbra Is Maintained at Buy by Truist Securities
Penumbra Analyst Ratings
Truist Financial Maintains Penumbra(PEN.US) With Buy Rating, Raises Target Price to $285
Oppenheimer Maintains Penumbra(PEN.US) With Buy Rating, Maintains Target Price $275
Penumbra Initiated at Outperform by Oppenheimer
Oppenheimer Initiates Penumbra(PEN.US) With Buy Rating, Announces Target Price $275
Citi Maintains Penumbra(PEN.US) With Hold Rating, Raises Target Price to $245
Wells Fargo Maintains Penumbra(PEN.US) With Buy Rating, Cuts Target Price to $275
Positive Outlook for Penumbra: Buy Rating Driven by THUNDER Trial Success and Market Growth Prospects
Penumbra Is Maintained at Buy by Canaccord Genuity